Related Experiment Video
Updated: Jan 31, 2026

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy
Bartosz Szostak1, Filip Machaj1, Jakub Rosik1
1a Department of Physiology , Pomeranian Medical University , Szczecin , Poland.
Introduction:
In cancer, the immune response to tumor antigens is often suppressed by inhibitors and ligands. Checkpoint blockade, considered one of the most promising frontiers for anti-cancer therapy, aims to stimulate the immune anti-cancer response. Agents such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors offer prolonged survival with manageable side effects.
Areas Covered:
We summarize the recent clinical successes of CTLA-4 inhibitors and place a strong emphasis on those in early phase clinical trials, often in combination with other immune check-point inhibitors, i.e., programmed cell death protein 1 (PD-1) and BRAF/mitogen-activated protein kinase inhibitors.
Expert Opinion:
Recent phase I and phase II clinical trials confirm the efficacy of anti-CTLA-4 therapy for treatment of cancers such as renal cell carcinoma. These studies also indicated increased efficacy with combined immune checkpoint blockade with PD-1 or Ras/Raf/mitogen-activated protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) inhibitors. Researchers must search for new immune targets that may enable more effective and safe immune checkpoint blockade and cancer therapy. This goal may be achieved by next-generation combination therapies to overcome immune checkpoint therapy resistance.
Insights
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors show promise in cancer therapy by stimulating anti-cancer immune responses. Combination therapies, including with PD-1 inhibitors, enhance efficacy and may overcome resistance.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Cancer immune evasion often involves suppressed responses to tumor antigens.
- Checkpoint blockade therapy aims to reactivate anti-cancer immunity.
- Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors are a key therapeutic strategy.
Purpose of the Study:
- To review clinical successes of CTLA-4 inhibitors.
- To highlight early-phase trials, particularly combination therapies.
- To discuss future directions for immune checkpoint blockade.
Main Methods:
- Review of recent phase I and phase II clinical trials.
- Analysis of combination therapies involving CTLA-4 inhibitors with PD-1 and BRAF/MAPK pathway inhibitors.
- Synthesis of expert opinions on overcoming therapeutic resistance.
Main Results:
- Anti-CTLA-4 therapy demonstrates efficacy in cancers like renal cell carcinoma.
- Combined immune checkpoint blockade with PD-1 or Ras/Raf/MEK/ERK inhibitors shows increased efficacy.
- Early-phase trials confirm the potential of these combined approaches.
Conclusions:
- CTLA-4 inhibitors are effective in cancer treatment, especially in combination regimens.
- Next-generation combination therapies are crucial for overcoming resistance to immune checkpoint blockade.
- Further research into novel immune targets is necessary for advancing cancer therapy.
Related Concept Videos
Phase Diagrams
Phase Transitions
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...

